Adentri

Adentri

CVT-124 Cardiology An adenosine A1 receptor antagonist in clinical trials in Pts with CHF. See Congestive heart failure.
References in periodicals archive ?
Adentri entered Phase III in August 2008 in acute decompensated heart failure (ADHF) patients with renal insufficiency.
The trial will evaluate ADENTRI, which is being developed under a licensing agreement with CV Therapeutics (Nasdaq: CVTX), or placebo in addition to standard of care in approximately 900 patients in 21 countries globally, including the United States.
The TRIDENT-1 (TReatment with Intravenous BG9928 for patients with acutely DEcompensated heart failure and reNal insufficiency Trial) study is a Phase III randomized, multi-center, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of IV ADENTRI dosed up to five days on body weight in ADHF patients with impaired renal function.
In previous clinical studies, ADENTRI has exhibited the potential to optimize fluid management without harmful effects on renal function.
We are excited to see ADENTRI enter into Phase III studies as one of Biogen Idec's lead cardiopulmonary programs," said Barry Ticho, M.
The commercial potential of ADENTRI is subject to a number of risks and uncertainties, including the risk of meeting the end points in clinical trials, other unexpected delays or hurdles, and the uncertainty of obtaining regulatory approval.
Results showed that administration of oral ADENTRI for 10 days, in addition to standard heart failure therapy, was well tolerated and resulted in clinically significant increases in sodium excretion while preserving renal function.
We are excited to have these data published showing the potential of ADENTRI in patients with heart failure.
We are moving forward with oral and intravenous formulations of ADENTRI for acute and chronic heart failure, as well as two additional compounds; LIXIVAPTAN for the treatment of hyponatremia in congestive heart failure and AVIPTADIL for the treatment of pulmonary arterial hypertension.
The trial was a randomized, double blind, placebo-controlled study that sought to assess the pharmacokinetics and pharmacologic effects of ADENTRI in heart failure patients.
Fifty patients were maintained on their usual medications, including ACE inhibitors and diuretics, and were dosed with placebo or one of four doses of ADENTRI, administered once daily for 10 days.
In addition, Biogen has ongoing Phase II studies for Amievive for treatment of moderate to severe psoriasis and Adentri, a novel diuretic agent.
Full browser ?